Scholarlink

<p>This retrospective cohort study aimed to elucidate the clinical significance of measuring autoantibodies against incretins in diabetes. We enrolled 274 patients with diabetes (mean age ± standard deviation [SD]: 63.1 ± 12.1&#xa0;years) and 109 healthy controls (mean age: 58.0 ± 5.8&#xa0;years). Titers of autoantibodies against incretins (glucose-dependent insulinotropic peptide and glucagon-like peptide-1) were measured using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Both incretin antibody titers were significantly higher in patients with diabetes than in healthy controls (both P &lt; 0.01). A mean 4.9-year (maximum 10-year) follow-up study revealed that patients who tested positive for glucose-dependent insulinotropic peptide antibodies had significantly worse prognoses than those who tested negative (P = 0.0072). Patients who tested positive for glucagon-like peptide-1 antibodies also tended to have worse prognoses (P = 0.06). To the best of our knowledge, this is the first study to investigate autoantibodies against incretin hormones in patients with diabetes. These autoantibodies may serve as novel prognostic biomarkers and provide a rationale for further studies on incretin-based therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Minoru Takemoto,
  • Bo-Shi Zhang,
  • Aiko Hayashi,
  • Hiroki Yamagata,
  • Yoich Yoshida,
  • Masaya Koshizaka,
  • Shunichiro Onishi,
  • Masaya Yamaga,
  • Tomohiko Yoshida,
  • Takahide Hashimoto,
  • Naoki Ohtake,
  • Takahiro Ishikawa,
  • Hirotaka Takizawa,
  • Takaki Hiwasa

摘要

This retrospective cohort study aimed to elucidate the clinical significance of measuring autoantibodies against incretins in diabetes. We enrolled 274 patients with diabetes (mean age ± standard deviation [SD]: 63.1 ± 12.1 years) and 109 healthy controls (mean age: 58.0 ± 5.8 years). Titers of autoantibodies against incretins (glucose-dependent insulinotropic peptide and glucagon-like peptide-1) were measured using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Both incretin antibody titers were significantly higher in patients with diabetes than in healthy controls (both P < 0.01). A mean 4.9-year (maximum 10-year) follow-up study revealed that patients who tested positive for glucose-dependent insulinotropic peptide antibodies had significantly worse prognoses than those who tested negative (P = 0.0072). Patients who tested positive for glucagon-like peptide-1 antibodies also tended to have worse prognoses (P = 0.06). To the best of our knowledge, this is the first study to investigate autoantibodies against incretin hormones in patients with diabetes. These autoantibodies may serve as novel prognostic biomarkers and provide a rationale for further studies on incretin-based therapies.